Skip to main content

Table 1 2012 European LeukemiaNet prognostic-risk group based on cytogenetic and molecular profile

From: PIM-1 mRNA expression is a potential prognostic biomarker in acute myeloid leukemia

Prognostic-risk group Cytogenetic profile alone Cytogenetic profile and molecular abnormalities
Favorable t(8:21)(q22; q22)
inv(16)(p13; 1q22)
t(15;17)(q22; q12)
t(8:21)(q22; q22) with no c-KIT mutation
inv(16)(p13; 1q22)
t(15;17)(q22; q12)
Mutated NPM1 without FLT3-ITD (CN-AML)
Mutated biallelic CEBPA (CN-AML)
Intermediate CN-AML
t(9;11)(p22; q23)
Cytogenetic abnormalities not included in the favorable or adverse prognostic risk groups
t(8:21)(q22;q22) with mutated c-KIT
CN-AML other than those included in the favorable or adverse prognostic group
t(9;11)(p22; q23)
Cytogenetic abnormalities not included in the favorable or adverse prognostic risk groups
Adverse inv(3)(q21q26.2)
t(6;9)(p23; q34)
11q abnormalities other than t(9;11)
−5 or del(5q)
−7
Complex karyotype
TP53 mutation, regardless of cytogenetic profile
CN with FLT3-ITD
CN with DNMT3A
CN with KMT2A-PTD
inv(3)(q21q26.2)
t(6;9)(p23;q34)
11q abnormalities other than t(9;11)
−5 or del(5q)
−7
Complex karyotype
  1. CN-AML normal cytogenetics acute myeloid leukemia, ITD internal tandem duplications